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Summary
Introduction: Salivary duct carcinoma is one of the rarest and most aggressive forms of parotid
tumor. We report two cases.
Cases: Case 1: a 78-year-old man was referred for a salivary duct carcinoma of the left parotid
gland. Treatment was surgical (parotidectomy with ipsilateral selective neck dissection), with-
out capsule rupture, and with healthy margins. At seven years’ follow-up, the patient was alive
and disease-free.
Case 2: a 41-year-old man was referred for a salivary duct carcinoma of the left parotid
gland. Parotidectomy with ipsilateral selective neck dissection left healthy but insufﬁcient
margins (< 1 cm), and postoperative radiation therapy (70Gy) was undertaken. At eight years’
follow-up, the patient was alive and free of recurrence.
Discussion: Mean patient age in the literature is 60 years, with a male-to-female ratio of 2:1.
Mean ﬁve-years’ recurrence-free survival was 34%.
Conclusion: Surgery is the main form of treatment in this indication. Postoperative radiation
therapy is indicated in case of extraparotid extension, pathological resection margins, cervi-
cal lymph node metastasis, lymphatic embolus and/or neurologic invasion. Chemotherapy is
generally reserved for metastatic forms of the disease.
© 2011 Elsevier Masson SAS. All rights reserved.
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alivary duct carcinoma was ﬁrst described in 1968 [1]. It
s an aggressive adenocarcinoma, resembling a high-grade
ammary duct carcinoma. Salivary gland sites are rare for
his epithelial tumor [2—4].
Two cases are reported and discussed in the light of the
iterature.
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78-year-old man was referred for painful swelling of
he left parotid region. On examination, the swelling was
rm, mobile and non-ﬁxed. The patient showed House
rade III facial palsy. The lymph node areas were free. On
T, the tumefaction in the exofacial part of the parotid
land, measuring about 18mm, with fuzzy contour, showed
oderate contrast-medium uptake. Treatment comprised
arotidectomy, not conserving the facial nerve (which was
nvaded), with selective ipsilateral lymph node curage (as
xtemporaneous histology suggested a malignant etiology).
he deﬁnitive histological examination diagnosed salivary
served.
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Figure 2 Anatomopathology slide of ﬁrst case specimen
(HES staining) (×100). This was a tumor formed of oncocytic
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and progesterone receptors and immunohistochemical
exploration for HER-2 protein may be contributive [7].
The most common clinical aspect is parotid tumefaction
which rapidly becomes progressive and is usually painful [3],Figure 1 Images of second case. T1-weighted gadolinium-
enhanced MRI: enhanced signal on tumor border.
duct carcinoma with exeresis margins exceeding 1 cm but
with perineural sheathing. The lymph node specimens were
healthy. There was no vascular embolism. The resection
margins were healthy; no adjuvant treatment was pre-
scribed. At seven years’ follow-up, the patient was alive
and without recurrence.
Case 2
A 41-year-old man was referred with two years’ history
of left parotid tumefaction. On examination, the tume-
faction was hard, with little mobility. Facial function was
normal. The lymph node areas were free. MRI (Fig. 1)
showed a multinodular exofacial parotid tumor of about
5 cm, in T1 isosignal with peripheral gadolinium enhance-
ment and T2 hypersignal. Treatment was surgical (total
parotidectomy conserving the facial nerve, with modi-
ﬁed ipsilateral radical cervical curage as extemporaneous
examination suggested a malignant etiology). Deﬁnitive his-
tological examination diagnosed salivary duct carcinoma
without lymphatic embolism or perineural sheathing. The
lymph node specimens were healthy. The resection margins
were healthy but less than 1 cm (and even less than 5mm on
certain slices); postoperative radiation therapy (70Gy) was
therefore undertaken. At eight years’ follow-up, the patient
was alive and free of recurrence.
Discussion
Salivary duct carcinoma represents 0.2% to 2% of parotid
tumors [2], and 6% to 10% of parotid cancers [3]. Onset is
generally in the ﬁfth or sixth decade of life, for a mean age of
60 years [3]. It mainly affects men, with a male-to-female
sex-ratio of 2:1. In some 20% of cases, it develops from a
F
s
cells with eosinophilic cytoplasm and nucleolated nuclei. Some
itoses were observed. The center of the duct was necrotic in
his case, giving a so-called comedo aspect.
re-existing benign lesion; it may, for example, result from
egeneration of a pleomorphic adenoma [3,4].
Macroscopically, the aspect is of a well-contoured
ellowish or grayish-white tumor that may be nodular,
ultinodular, cystic or inﬁltrating, surrounded by ﬁbrosis
ith hemorrhagic areas, necrosis and cystic degenera-
ion [3]. There may be intratumoral calciﬁcation [3,5].
he most frequent histologic forms are comedonecrotic
Fig. 2), papillary or cribriform (Fig. 3) [4,6]. There is also
ntraduct cellular proliferation with eosinophilic cytoplasm
uclear polymorphism showing some mitoses and an ele-
ated nuclear-cytoplasmic ratio [3]. Differential diagnoses
omprise mucoepidermoid carcinoma and mammary adeno-
arcinoma metastasis. In case of doubt, studying estrogenigure 3 Anatomopathology slide of ﬁrst case specimen (HES
taining) (×100). Typical cribriform disposition of a salivary duct
arcinoma.
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[10] Sato K, Shimode Y, Itoi A, et al. Salivary duct carcinoma
of the parotid gland presenting KIT (CD117) overexpression.96
ard on palpation, measuring about 3 cm and possibly reach-
ng 9 to 10 cm at diagnosis [6]. Facial palsy, expressing the
ocal aggressiveness of the tumor, is found in almost half of
ases at diagnosis [6]. Lymph node invasion is also found in
0% to 80% of cases [4].
Radiologically, calciﬁcation may be found in the primi-
ive lesion [3]. MRI ﬁnds a uni or multinodular tumor in T1
sosignal and T2 isosignal, strongly enhanced by gadolinium
Fig. 1).
The invasive nature of salivary duct carcinoma requires
adical treatment. This is based on surgical removal by
otal parotidectomy with or without conservation of the
acial nerve, depending on its involvement, associated to
psilateral lymph node curage. The rate of locoregional
ailure is high [4]. Invaded or insufﬁcient resection mar-
ins, lymphatic embolism, perineural invasion, extraparotid
nd/or lymphatic invasion, local and/or regional recur-
ence and metastasis are factors of poor prognosis for
urvival [4,8—10], and in these cases postoperative radiation
herapy is mandatory. Chemotherapy is generally reserved
or metastatic forms. Prognosis is better in tumors measuring
ess than 2 cm [4,8]. Five-year recurrence-free survivorship
s about 30% [2,6].
onclusion
alivary duct carcinoma is an aggressive malignant tumor for
hich treatment is essentially surgical. Adjuvant radiation
herapy is reserved to evolved forms.isclosure of interest
he authors declare that they have no conﬂicts of interest
oncerning this article.Y. Pons et al.
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